A single injection of a small, circular piece of DNA has been shown to control weight and blood sugar for months in mice, according to a study from The Wistar Institute. The approach could eventually eliminate the need for weekly shots of GLP-1 drugs like Ozempic and Wegovy if it proves safe and effective in human trials. The research represents a early-stage step toward a longer-lasting treatment for obesity and type 2 diabetes.

  • A single DNA-based injection produced weight loss and glucose control in mice that lasted up to 10 times longer than current weekly GLP-1 drugs.
  • The treatment uses a small, circular piece of genetic instruction to prompt the body to produce a GLP-1-like hormone continuously for months.
  • Human clinical trials are needed to determine if the approach is safe and effective in people.
  • If successful, the method could improve patient adherence by reducing the need for frequent injections.

What Is This New DNA Approach?

Researchers at The Wistar Institute designed a small, circular piece of DNA called a plasmid. The plasmid carries a genetic instruction for the body to produce a protein similar to GLP-1, the hormone that GLP-1 drugs mimic. Once injected, the DNA enters cells and acts like a mini factory, releasing the hormone steadily for months. The therapy is not a vaccine but a type of gene therapy that delivers a blueprint for making a therapeutic protein.

How Was the Study Conducted?

The study used mouse models of obesity and diabetes. A single injection of the DNA plasmid was given to the mice. Researchers then tracked their weight and blood glucose levels over time. Compared with mice receiving conventional weekly GLP-1 drugs, the DNA-treated mice maintained weight loss and blood sugar control for a period roughly 10 times longer. The effects lasted for months rather than days or weeks, the report states.

Why Does This Matter for GLP-1 Therapy?

Current GLP-1 drugs such as Ozempic and Wegovy require weekly injections. Many patients find it difficult to stick to this schedule, and lapses can lead to regaining weight or losing blood sugar control. A treatment that works for months after a single injection could dramatically improve adherence. It could also reduce the burden of repeated doctor visits and the cost of frequent medication supplies, though the upfront price of a DNA therapy might be higher.

What Are the Next Steps?

The results are only from mouse studies. The Wistar Institute team plans to move toward human trials, but safety and dosing must be tested first. DNA-based therapies can sometimes trigger immune reactions or cause unintended effects if the genetic instruction does not turn off properly. The researchers will need to show that the approach is safe in larger animals and eventually in humans before it could become a treatment option.

Frequently Asked Questions

Is this DNA injection the same as gene therapy?

Yes, this approach is a form of gene therapy. It uses a small, circular piece of DNA (a plasmid) to instruct cells to produce a GLP-1-like protein. It does not permanently alter a person's genome, but it does provide a long-lasting source of the therapeutic protein. Gene therapies are still an emerging field, and long-term safety data is limited.

How long do the effects last compared to weekly shots?

In the mouse study, a single DNA injection produced effects lasting up to 10 times longer than a typical weekly GLP-1 drug. The exact duration in humans cannot be predicted from animal data, but the researchers expect that one injection could provide benefits for several months if the mechanism translates similarly.

When might this treatment be available for people?

Human clinical trials have not yet started. Even if early trials succeed, it typically takes years of testing and regulatory review before a new therapy becomes available. A realistic timeline would be at least five to ten years, assuming no major safety or manufacturing hurdles arise.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.